

A VERSATILE SYNTHESIS OF ARYLACETONES FROM ARYL HALIDES AND ACETYLACETONATE

Saburo SUGAI,* Hiroshi IKAWA, Tokuji OKAZAKI, Sanya AKABOSHI, and
Shiro IKEGAMI†

Research Laboratories, Ohta Pharmaceutical Co.,Ltd.,
Namiki, Kawaguchi 332, and

†Faculty of Pharmaceutical Sciences, Teikyo University,
Sagamiko, Kanagawa 199-01


Reaction of aryl halides with sodium or potassium acetylacetonate in the presence of a copper catalyst affords directly arylacetones resulted from deacetylation of initially formed 3-arylacetylacetones in good yields.

An investigation of a new efficient synthetic method of arylacetones gives us interesting useful intermediates for drug synthesis of central nervous system agents. In this paper, we wish to report an efficient, direct synthesis of arylacetones from the reactions of aryl halides with acetylacetonate.

Some preparations of arylacetones have been reported.¹⁻⁴⁾ However, these reactions mostly need drastic conditions and a few or more steps, and generally afford the corresponding products only in moderate or poor yields. Hence, particularly, in manufacturing scale, they would be less useful. Thus, we were interested in the utility of acetylacetonate as a reagent convertible easily to an acetyl group and studied reactions with aryl halides.

The reaction of acetylacetonate with aryl halides has been hitherto known only in cases of aryl halides substituted with a carboxyl group in the ortho-position in the presence of Cu(II) derived from disproportionation of Cu(I).^{5,6)} In such a case, it was presumed that a carboxylate anion would be concerned in the reaction.⁵⁾

We investigated the direct arylation of acetylacetonate with aryl halides without the aid of such a carboxyl group. Consequently, we could obtain 3-arylacetylacetones from the reaction in the presence of Cu(I) halide. Since these 3-arylacetylacetones trend to deacetylate under alkaline condition, subsequent deacetylation in diluted alkaline solution in the same pot afforded the corresponding arylacetones in good yields. This procedure must be simple because two steps reactions can be performed in a one-pot.



A typical procedure is as follows: 3-bromobenzophenone(5 mmol) was dissolved in 15 ml of dry dimethylformamide, then CuI(5 mmol) and potassium acetylacetonate(25 mmol)⁷⁾

were added successively under a nitrogen current. The reaction mixture was heated for 6 hr at 100°C to afford a mixture of 3-acetylbenzophenone, bp_{1.0} 177-181°C; $\nu_{\text{C=O}}$ 1715, 1650; δ in CDCl₃ 2.16(3H,s,CH₃), 3.75(2H,s,CH₂), 7.30-7.85(9H,m,aromatic); M⁺ 238, and 3-(3-benzoylphenyl)acetylacetone, $\nu_{\text{C=O}}$ 1650, 1600; δ in CDCl₃ 1.86(6H,s,CH₃x2), 7.30-7.80(10H,m,aromatic and CH); M⁺ 280, in 60 and 14% yields, respectively. The latter acetylacetone compound was quantitatively converted to 3-acetylbenzophenone by treatment with diluted NaOH aq. solution at room temperature. After usual work-up, the products were purified by silica-gel column chromatographic technique.

Usually this procedure could be successively performed in the same reaction vessel without isolation of both compounds. The results obtained using various aryl halides under several different conditions are summarized in Table I.

Table I

Entry	$\overset{1}{\sim}$ ArX	$\overset{2}{\sim}$ M	$\overset{3}{\sim}$ Y	Time(hr)	$\overset{4}{\sim}$ ^{a)} Yield(%) ^{b)}	$\overset{5}{\sim}$ ^{a)} Yield(%) ^{b)}
1	3-PhCOC ₆ H ₄ Br	K	I	6.0	14 ^{c)}	60 ^{c)}
2	3-PhCOC ₆ H ₄ Br	K	Br	7.5		80
3	3-PhCOC ₆ H ₄ Br	K	Cl	11.0		76
4	3-AcC ₆ H ₄ Br	Na	I	15.0		81
5	4-AcC ₆ H ₄ Br	Na	I	15.0		66
6	4-NO ₂ C ₆ H ₄ Br	Na	I	1.5		43
7	3-F-4-PhC ₆ H ₄ Br	Na	I	14.0		67
8	PhBr	Na	I	30.0		72
9	2-CH ₃ C ₆ H ₄ Br	Na	I	48.0		32
10	4-CH ₃ C ₆ H ₄ Br	Na	I	23.0	10 ^{c)}	65 ^{c)}
11	4-CH ₃ C ₆ H ₄ Br	K	I	9.0		85
12	4-CH ₃ C ₆ H ₄ I	K	I	2.0		82
13	4-CH ₃ OC ₆ H ₄ Br	Na	I	23.0	26 ^{c)}	67 ^{c)}
14	4-AcNHC ₆ H ₄ Br	Na	I	27.0		82 ^{d)}

a) Mp and bp of new product: Entry 7 (5); mp 74.5-75.5°C, Entry 13 (4); bp_{7.0} 130-134°C. b) Isolated yield. c) Yield resulted from the initial reaction is shown. d) Used 2 equiv. of 3.

As shown in Table I, it is indicated that the combination of cuprous iodide and potassium acetylacetonate gives the best result.

In this reaction, the differences of reaction conditions in changes of solvent, temperature, and catalyst would seriously affect the formation of product. The use of a protic solvent did not result in the formation of the desired product, but afforded the corresponding reduced product as a major product. Therefore, aprotic solvents having high solubility such as dimethylformamide should be desired in this reaction.

The reaction temperature over 120°C should be avoided because the decomposition of acetylacetonate might be caused.

Next, we found that the reaction proceeded not only in the presence of Cu(I) halides as a catalyst, but also in the reaction with Cu(II) acetylacetonate resulted from disproportionation. The catalytic abilities of Cu(II) and Cu(0) were also

investigated for exploiting the reaction process.

Based on the information that the formation of Cu(0) and Cu(II) acetylacetonate have been anticipated in our system, we investigated these catalytic abilities for the substitution reaction of acetylacetonate with 3-bromobenzophenone. The reaction of 3-bromobenzophenone (1 eq. mol) with or without potassium acetylacetonate (4 eq. mol) was carried out in dimethylformamide at 100°C in the presence or absence of Cu(0), Cu(I) or Cu(II) as a catalyst. After the reaction, 3-(3-benzoylphenyl)acetylacetonate formed was successively deacetylated by treatment with diluted NaOH aq. solution in the same vessel. These results are summarized in Table II.




Table II


Run	Catalyst (Molar Ratio)	Time (hr)	Yield (%) ^{a)} of 5a
1	Cu ²⁺ (CHAc ₂) ₂ (1)	24	no reaction ^{b)}
2	_____	24	trace ^{c,d)}
3	Cu ²⁺ (CHAc ₂) ₂ (0.5)	11	61
4	Cu ²⁺ (CHAc ₂) ₂ (0.5) + Cu(0) (0.5)	11	61
5	Cu ²⁺ (CHAc ₂) ₂ (0.5) + KI (1)	7	77
6	CuI (1)	7	74 ^{e)}
7	Cu(0) (0.1)	20	trace ^{d)}

a) Isolated yield. b) In the absence of $\underset{\sim}{2}$. c) In the absence of a catalyst.

d) Detected by TLC and GLC. e) Used 5 equiv. of $\underset{\sim}{2}$.

The substitution reaction could not completely take place with only Cu(II) acetylacetonate formed by the disproportionation (Run 1). Furthermore, 3-bromobenzophenone was hardly substituted with only use of potassium acetylacetonate (Run 2). In addition, Cu(0) exhibited little catalytic activity (Run 7). Apparently, in the promotion of the present reaction, the presence of Cu(I) and/or Cu(II) would be essential. The catalytic activity of Cu(I) appears to be equal or greater than that of Cu(II), and the addition of potassium iodide may accelerate the rate due to the activation of Cu(II).

An application to the synthesis of drugs was attempted as follows. For example, as shown in the following scheme, 2-(3-benzoylphenyl)propionic acid (**7**), a potent anti-inflammatory agent, could be obtained in 88% yield from **5a** in only two steps.⁸⁾




The present, new efficient synthetic method of arylacetones would provide a some class of synthetic intermediates useful for drug syntheses.

References

- 1) a) R.M.Hebst and R.H.Manske, *Org. Synthesis*, 16, 47(1936). b) J.M.Potapov and A.P.Terenteo, *Zh. Obshch. Khim.*, 28, 3323(1958).
- 2) C.Tegner, *Acta Chem. Scand.*, 6, 782(1952).
- 3) M.E.Dullaghan and F.F.Nord, *J. Org. Chem.*, 18, 878(1953).
- 4) J.Smidt, W.Hafner, and R.Jiva, *U.S.Patent*, 3,080,425(1963).
- 5) R.G.R.Bacon and J.C.F.Murray, *J. Chem. Soc., Perkin Trans. 1*, 1975, 1267.

A mechanism concerning the reaction of ortho-bromobenzoic acid with Cu(II) acetylacetonate has been presented as follows.



- 6) R.Nast, R.Mohr, and C.Schultze, *Chem. Ber.*, 96, 2127(1963).
- 7) Sodium and potassium acetylacetonates prepared from the reaction of acetylacetone with an equimolar amount of NaOH or KOH dissolved in ethanol, followed by drying the isolated salts under reduced pressure, were used. Commercially available cuprous halides were directly used without further treatment.
- 8) A part of this work was presented at the 101st Annual Meeting of Pharmaceutical Society of Japan, Kumamoto, April 1981.

(Received January 6, 1982)